Emergency Use Authorization of Remdesivir The Need for a Transparent Distribution Process

被引：48

作者：

Ison, Michael G. ^{[1
,2
]}

Wolfe, Cameron ^{[3
]}

Boucher, Helen W. ^{[4
,5
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA

[2] Northwestern Univ, Feinberg Sch Med, Div Organ Transplantat, Chicago, IL 60611 USA

[3] Duke Univ, Sch Med, Div Infect Dis, Durham, NC USA

[4] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA

[5] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2020年 / 323卷 / 23期

关键词：

PERAMIVIR;

D O I：

10.1001/jama.2020.8863

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

This Viewpoint reviews the FDA's May 2020 Emergency Use Authorization of the antiviral drug remdesivir for treatment of COVID-19 and discusses the need for a transparent distribution plan of a drug not otherwise available in the US and for which demand will likely exceed supply.

引用

页码：2365 / 2366

页数：2

共 4 条

[1]

The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza [J].

Birnkrant, Debra ;

Cox, Edward .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) :2204-2207

[2]

The Equitable Distribution of COVID-19 Therapeutics and Vaccines [J].

Bollyky, Thomas J. ;

Gostin, Lawrence O. ;

Hamburg, Margaret A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (24) :2462-2463

[3]

Infectious Diseases Society of America, REMD EUA LETT

[4]

Emergency Use Authorization for Intravenous Peramivir: Evaluation of Safety in the Treatment of Hospitalized Patients Infected With 2009 H1N1 Influenza A Virus [J].

Sorbello, Alfred ;

Jones, S. Christopher ;

Carter, Wendy ;

Struble, Kimberly ;

Boucher, Robert ;

Truffa, Melissa ;

Birnkrant, Debra ;

Gada, Neha ;

Camilli, Sara ;

Chan, Irene ;

Dallas, Scott ;

Scales, Twanda ;

Kosko, Robert ;

Thompson, Elizabeth ;

Goodman, Jesse ;

Francis, Henry ;

Dal Pan, Gerald .

CLINICAL INFECTIOUS DISEASES, 2012, 55 (01) :1-7

← 1 →